ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0149

Durability of SARS-CoV-2 Spike Antibody Levels in Dialysis Patients After COVID-19 Infection

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Manley, Harold J., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Hsu, Caroline M., Tufts University School of Medicine, Boston, Massachusetts, United States
  • Aweh, Gideon N., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Weiner, Daniel E., Tufts University School of Medicine, Boston, Massachusetts, United States
  • Frament, Jill M., Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Ladik, Vladimir, Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Johnson, Doug, Dialysis Clinic Inc, Nashville, Tennessee, United States
  • Lacson, Eduardo K., Dialysis Clinic Inc, Nashville, Tennessee, United States
Background

Durability of SARS-CoV-2 receptor-binding domain spike antibody (RBD s-Ab) levels among patients receiving dialysis after COVID-19 [WDE(1] is unknown[EL2] beyond 6 months. We describe the persistence (index value ≥ 1 and ≥ 2 U/L) of semi-quantitative RBD s-Ab levels in dialysis patients over 14 month period.

Methods

All maintenance dialysis patients (>18 years old) within Dialysis Clinic, Inc. 260 clinics in 28 states with COVID-19 infection history and RBD s-Ab levels determined between Jan 1 and May 23, 2021 were included. On the day of RBD s-Ab level determination, patient demographics (age, sex, race, modality, ESKD vintage) and days since COVID-19 diagnosis were determined. Patient RBD s-Ab levels obtained after COVID-19 vaccination were excluded.

Results

A total of 515 patients, mean age 62±14 years, 57% male, 46% White, 94% HD and vintage 4.6±4.4 years[EL1] ,[HJM2] had 835 RBD s-Ab levels assessed at a median of 59 days (range 0-422 days) post COVID-19 diagnosis. RBD s-Ab levels were assessed 1, 2 or ≥3 times in 64%, 18% and 18% patients, respectively. Only 32 (6.2%) patients had undetectable RBD s-Ab on the last draw. A cross sectional summary of the last available RBD s-Ab levels suggests that titers remain detectable for long duration (Figure[EL3] [HJM4] ). In patients (N=186; 36%) with multiple RBD s-Ab levels (mean 28±15; median 28 days between levels), subsequent values were higher, lower [EL5] [HJM6] or unchanged 7%, 16% and 77% of time[EL7] , respectively.

Conclusion

Most maintenance dialysis patients sampled developed SARS-CoV-2 RBD s-Ab after COVID diagnosis, and durability extends up to 14 months. Further elucidation of longitudinal RBD s-Ab values post-COVID-19 infection as well as after completing vaccination for SARS-CoV-2 is needed.